Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder

Genetics and Molecular Biology

Volumn 33, Issue 3, 2010, Pages 460-462

  Pljesa Ercegovac, Marija ^a   Savic Radojevic, Ana ^a   Kravic Stevovic, Tamara ^a   Bumbasirevic, Vladimir ^a   Mimic Oka, Jasmina ^a   Simic, Tatjana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Co localization; Glutathione S transferase; JNK; TCC

Indexed keywords

GLUTATHIONE TRANSFERASE P1; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

EID: 77957316897     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572010005000063     Document Type: Article

References (19)

1. Adler V and Pincus MR (2004) Effector peptides from glutathione S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci 34:35-46.
2. Berendsen CL, Peters WH, Scheffer PG, Bouman AA, Boven E and Newling DW (1997) Glutathione S-transferase activity and subunit composition in transitional cell cancer and mucosa of the human bladder. Urology 49:644-651.
3. Burg D, Riepsaame J, Pont C, Mulder G and Van de Water B (2006) Peptide bond modified glutathione conjugate analogs modulate GST pi function in glutathione-conjugation, drug sensitivity and JNK signaling. Biochem Pharmacol 71:268-277.
4. Castro-Caldas M, Milagre I, Rodrigues E and Gama MJ (2009) Glutathione S-transferase pi regulates UV-induced JNK signaling in SH-SY5Y neuroblastoma cells. Neurosci Lett 451:241-245.
5. Cui H, Shen J, Lu D, Zhang T, Zhang W, Sun D and Wang PG (2008) 4-Aryl-1,3,2-oxathiazolylium-5-olate: A novel GST inhibitor to release JNK and activate c-Jun for cancer therapy. Cancer Chemother Pharmacol 62:509-515.
6. Gate L and Tew KD (2001) Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 5:477-489.
7. Hayes JD and Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154-166.
8. Lo HW and Ali-Osman F (2007) Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 7:367-374.
9. Pljesa-Ercegovac M, Savic-Radojevic A, Dragicevic D, Mimic-Oka J, Matic M, Sasic T, Pekmezovic T, Vuksanovic A and Simic T (2009) Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways. Urol Oncol (in press) 10.1016/j.urolonc.2008.10.019.
10. Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L, Filomeni G, Federici G and Caccuri AM (2005) 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. J Biol Chem 280:26397-26405.
11. Savic-Radojevic A, Mimic-Oka J, Pljesa-Ercegovac M, Opacic M, Dragicevic D, Kravic T, Djokic M, Micic S and Simic T (2007) Glutathione S-transferase P1 expression correlates with increased antioxidant capacity in transitional cell carcinoma of the urinary bladder. Eur Urol 52:470-477.
12. Simic T, Mimic-Oka J, Savic-Radojevic A, Opacic M, Pljesa M, Dragicevic D, Djokic M and Radosavljevic R (2005) Glutathione S-transferase T1-1 activity upregulated in transitional cell carcinoma of urinary bladder. Urology 65:1035-1040.
13. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M and Mimic-Oka J (2009) Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol 6:281-289.
14. Tew KD (2005) TLK-286: A novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047-1054.
15. Townsend D and Tew K (2003) The role of glutathione S-transferase in anti-cancer drug resistance. Oncogene 22:4369-4675.
16. Turella P, Cerella C, Filomeni G, Bullo A, De Maria F, Ghibelli L, Ciriolo MR, Cianfriglia M, Mattei M, Federici G et al. (2005) Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 65:3751-3761.
17. Vergote I, Finkler N, Del Campo J, Lohr A, Hunter J, Matei D, Spriggs D, Kavanagh J, Vermorken J, Brown GL et al. (2007) Single agent, canfosfamide (C, TLK286) vs. pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results. J Clin Oncol 25:LBA5528 [Abstract].
18. Wang T, Arifoglu P, Ronai Z and Tew K (2001) Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 276:20999-21003.
19. Yang CR, Ou YC, Kuo JH, Kao YL, Chen CL, Yean SY, Horng YY and Yang CS (1997) Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response. Cancer Lett 119:157-162.